Miller Howard Investments Inc. NY Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Miller Howard Investments Inc. NY lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 942,729 shares of the biopharmaceutical company’s stock after selling 115,348 shares during the quarter. Gilead Sciences accounts for approximately 2.9% of Miller Howard Investments Inc. NY’s investment portfolio, making the stock its 6th biggest position. Miller Howard Investments Inc. NY owned about 0.08% of Gilead Sciences worth $87,080,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Empowered Funds LLC boosted its position in Gilead Sciences by 55.8% during the 4th quarter. Empowered Funds LLC now owns 219,579 shares of the biopharmaceutical company’s stock worth $20,283,000 after buying an additional 78,657 shares during the period. Wilmington Savings Fund Society FSB boosted its holdings in shares of Gilead Sciences by 6.8% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 19,933 shares of the biopharmaceutical company’s stock worth $1,841,000 after buying an additional 1,273 shares in the last quarter. Arlington Financial Advisors LLC increased its stake in shares of Gilead Sciences by 2.0% in the 4th quarter. Arlington Financial Advisors LLC now owns 47,020 shares of the biopharmaceutical company’s stock valued at $4,343,000 after acquiring an additional 915 shares in the last quarter. D Orazio & Associates Inc. boosted its stake in Gilead Sciences by 39.6% during the fourth quarter. D Orazio & Associates Inc. now owns 4,082 shares of the biopharmaceutical company’s stock worth $377,000 after acquiring an additional 1,158 shares in the last quarter. Finally, Kingsview Wealth Management LLC grew its holdings in Gilead Sciences by 110.9% in the fourth quarter. Kingsview Wealth Management LLC now owns 42,014 shares of the biopharmaceutical company’s stock worth $3,881,000 after purchasing an additional 22,091 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GILD shares. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. UBS Group boosted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Finally, Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 2.0 %

Shares of NASDAQ GILD opened at $96.04 on Friday. The business has a 50-day simple moving average of $93.04 and a two-hundred day simple moving average of $86.65. The company has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the company earned $2.29 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.